Leveraging an RNAi Solution to target Integrins in Scarring and Chronic Fibrosis
- Leveraging self-delivering siRNA technology to silence a novel integrin target that drives the pathological switch to chronic fibrosis
- Unlocking regenerative healing by reversing myofibroblast persistence
- Validating a new treatment paradigm to demonstrate potent target knockdown and functional recovery in models of fibrotic disease